

The challenge of value-based pricing in combination therapy with trastuzumab and pertuzumab in HER2+ metastatic breast cancer

Expert Review of Pharmacoeconomics and Outcomes Research
21, 497-504

DOI: [10.1080/14737167.2021.1896968](https://doi.org/10.1080/14737167.2021.1896968)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2022, 8, 597.	3.4	15